Genetic variants of Nogo-66 receptor with possible association to schizophrenia block myelin inhibition of axon growth

Journal of Neuroscience

Volumn 28, Issue 49, 2008, Pages 13161-13172

  Budel, Stéphane ^a   Padukkavidana, Thihan ^a   Liu, Betty P ^a   Feng, Zeny ^a,b   Hu, Fenghua ^a   Johnson, Sam ^a   Lauren, Juha ^a   Park, James H ^a   McGee, Aaron W ^a   Liao, Ji ^a   Stillman, Althea ^a   Kim, Ji Eun ^a   Yang, Bao Zhu ^a   Sodi, Stefano ^a   Gelernter, Joel ^a   Zhao, Hongyu ^a   Hisama, Fuki ^a   Arnsten, Amy F T ^a   Strittmatter, Stephen M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF GUELPH   (Canada)

Author keywords

Axonal growth; Genetic linkage; Myelin; Nogo; Plasticity; Schizophrenia

Indexed keywords

DNA; MYELIN; NOGO 66 RECEPTOR; CELL SURFACE RECEPTOR; GROWTH INHIBITOR; MYELIN PROTEIN; RTN4R PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; COGNITION; CONTROLLED STUDY; GENE LOCUS; GENE SEQUENCE; GENETIC LINKAGE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MOUSE; NERVE CELL PLASTICITY; NERVE FIBER GROWTH; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RISK ASSESSMENT; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; WORKING MEMORY; ANIMAL; BRAIN; CELL STRAIN COS1; CERCOPITHECUS; CHICK EMBRYO; CHROMOSOME MAP; CODON; FEMALE; GENETIC PREDISPOSITION; GENETICS; GROWTH CONE; MALE; METABOLISM; MOUSE MUTANT; MUTATION; MYELINATED NERVE; NERVOUS SYSTEM DEVELOPMENT; ORGAN CULTURE TECHNIQUE; PATHOPHYSIOLOGY; RAT; ULTRASTRUCTURE;

ANIMALS; BRAIN; CERCOPITHECUS AETHIOPS; CHICK EMBRYO; CHROMOSOME MAPPING; CODON; COS CELLS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GROWTH CONES; GROWTH INHIBITORS; HUMANS; MALE; MICE; MICE, KNOCKOUT; MUTATION; MYELIN PROTEINS; NERVE FIBERS, MYELINATED; NEUROGENESIS; NEURONAL PLASTICITY; ORGAN CULTURE TECHNIQUES; RATS; RECEPTORS, CELL SURFACE; SCHIZOPHRENIA;

EID: 58149376506     PISSN: 02706474     EISSN: 02706474     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.3828-08.2008     Document Type: Article

References (77)

1. Akil M, Kolachana BS, Rothmond DA, Hyde TM, Weinberger DR, Kleinman JE (2003) Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. J Neurosci 23:2008-2013.
2. Baron M (2001) Genetics of schizophrenia and the new millennium: progress and pitfalls. Am J Hum Genet 68:299-312.
3. Barton WA, Liu BP, Tzvetkova D, Jeffrey PD, Fournier AE, Sah D, Cate R, Strittmatter SM, Nikolov DB (2003) Structure and axon outgrowth inhibitor binding of the Nogo-66 receptor and related proteins. EMBO J 22:3291-3302.
4. Bassett AS, Chow EW (1999) 22q11 deletion syndrome: a genetic subtype of schizophrenia. Biol Psychiatry 46:882-891.
5. Bassett AS, Chow EW (2008) Schizophrenia and 22q11.2 deletion syndrome. Curr Psychiatry Rep 10:148-157.
6. Bassett AS, Chow EW, AbdelMalik P, Gheorghiu M, Husted J, Weksberg R (2003) The schizophrenia phenotype in 22q11 deletion syndrome. Am J Psychiatry 160:1580-1586.
7. Benes FM, Davidson J, Bird ED (1986) Quantitative cytoarchitectural studies of the cerebral cortex of schizophrenics. Arch Gen Psychiatry 43:31-35.
8. Cafferty WB, Strittmatter SM (2006) The Nogo-Nogo receptor pathway limits a spectrum of adult CNS axonal growth. J Neurosci 26:12242-12250.
9. Cafferty WB, Kim JE, Lee JK, Strittmatter SM (2007) Response to correspondence: Kim et al., "axon regeneration in young adult mice lacking Nogo-A/B." Neuron 38, 187-199. Neuron 54:195-199.
10. Cafferty WB, McGee AW, Strittmatter SM (2008) Axonal growth therapeutics: regeneration or sprouting or plasticity? Trends Neurosci 31:215-220.
11. Chakravarti A (2002) A compelling genetic hypothesis for a complex disease: PRODH2/DGCR6 variation leads to schizophrenia susceptibility. Proc Natl Acad Sci U S A 99:4755-4756.
12. Chivatakarn O, Kaneko S, He Z, Tessier-Lavigne M, Giger RJ (2007) The Nogo-66 receptor NgR1 is required only for the acute growth cone-collapsing but not the chronic growth-inhibitory actions of myelin inhibitors. J Neurosci 27:7117-7124.
13. Cohen E, Chow EW, Weksberg R, Bassett AS (1999) Phenotype of adults with the 22q11 deletion syndrome: a review. Am J Med Genet 86:359-365.
14. Davis KL, Haroutunian V (2003) Global expression-profiling studies and oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 362:758.
15. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, Goldman D, Weinberger DR (2001) Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 98:6917-6922.
16. Fournier AE, GrandPré T, Strittmatter SM (2001) Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration. Nature 409:341-346.
17. Fournier AE, Gould GC, Liu BP, Strittmatter SM (2002) Truncated soluble Nogo receptor binds Nogo-66 and blocks inhibition of axon growth by myelin. J Neurosci 22:8876-8883.
18. Franowicz JS, Kessler LE, Borja CM, Kobilka BK, Limbird LE, Arnsten AF (2002) Mutation of the α2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine. J Neurosci 22:8771- 8777.
19. Gogos JA, Morgan M, Luine V, Santha M, Ogawa S, Pfaff D, Karayiorgou M (1998) Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci U S A 95:9991-9996.
20. GrandPré T, Li S, Strittmatter SM (2002) Nogo-66 receptor antagonist peptide promotes axonal regeneration. Nature 417:547-551.
21. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, Haroutunian V, Fienberg AA (2001) Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A 98:4746-4751.
22. He XL, Bazan JF, McDermott G, Park JB, Wang K, Tessier-Lavigne M, He Z, Garcia KC (2003) Structure of the Nogo receptor ectodomain: a recognition module implicated in myelin inhibition. Neuron 38:177-185.
23. Hof PR, Haroutunian V, Copland C, Davis KL, Buxbaum JD (2002) Molecular and cellular evidence for an oligodendrocyte abnormality in schizophrenia. Neurochem Res 27:1193-1200.
24. Hsu R, Woodroffe A, Lai WS, Cook MN, Mukai J, Dunning JP, Swanson DJ, Roos JL, Abecasis GR, Karayiorgou M, Gogos JA (2007) Nogo receptor 1 (RTN4R) as a candidate gene for schizophrenia: analysis using human and mouse genetic approaches. PLoS ONE 2:e1234.
25. Hulshoff Pol HE, Schnack HG, Mandl RC, Cahn W, Collins DL, Evans AC, Kahn RS (2004) Focal white matter density changes in schizophrenia: reduced inter-hemispheric connectivity. Neuroimage 21:27-35.
26. Hunt D, Mason MR, Campbell G, Coffin R, Anderson PN (2002) Nogo receptor mRNA expression in intact and regenerating CNS neurons. Mol Cell Neurosci 20:537-552.
27. Jacquet H, Raux G, Thibaut F, Hecketsweiler B, Houy E, Demilly C, Haouzir S, Allio G, Fouldrin G, Drouin V, Bou J, Petit M, Campion D, Frébourg T (2002) PRODH mutations and hyperprolinemia in a subset of schizophrenic patients. Hum Mol Genet 11:2243-2249.
28. Josephson A, Trifunovski A, Widmer HR, Widenfalk J, Olson L, Spenger C (2002) Nogo-receptor gene activity: cellular localization and developmental regulation of mRNA in mice and humans. J Comp Neurol 453:292-304.
29. Karayiorgou M, Morris MA, Morrow B, Shprintzen RJ, Goldberg R, Borrow J, Gos A, Nestadt G, Wolyniec PS, Lasseter VK (1995) Schizophrenia susceptibility associated with interstitial deletions of chromosome 22q11. Proc Natl Acad Sci U S A 92:7612-7616.
30. Karoutzou G, Emrich HM, Dietrich DE (2007) The myelin-pathogenesis puzzle in schizophrenia: a literature review. Mol Psychiatry 13:245-260.
31. Keedy SK, Ebens CL, Keshavan MS, Sweeney JA (2006) Functional magnetic resonance imaging studies of eye movements in first episode schizophrenia: smooth pursuit, visually guided saccades and the oculomotor delayed response task. Psychiatry Res 146:199-211.
32. Keefe RSE, Bilder RM, Harvey PD, Davis SM, Palmer BW, Gold JM, Meltzer HY, Green MF, Miller DD, Canive JM, Adler LW, Manschreck TC, Swartz M, Rosenheck R, Perkins DO, Walker TM, Stroup TS, McEvoy JP, Lieberman JA (2006) Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology 31:2033-2046.
33. Kim JE, Liu BP, Park JH, Strittmatter SM (2004) Nogo-66 receptor prevents raphespinal and rubrospinal axon regeneration and limits functional recovery from spinal cord injury. Neuron 44:439-451.
34. Kubicki M, Westin CF, Nestor PG, Wible CG, Frumin M, Maier SE, Kikinis R, Jolesz FA, McCarley RW, Shenton ME (2003) Cingulate fasciculus integrity disruption in schizophrenia: a magnetic resonance diffusion tensor imaging study. Biol Psychiatry 54:1171-1180.
35. Larsen JK, Divac I (1978) Selective ablations within the prefrontal cortex of the rat and performance of delayed alternation. Physiol Psychol 6:15-17.
36. Laurén J, Hu F, Chin J, Liao J, Airaksinen MS, Strittmatter SM (2007) Characterization of myelin ligand complexes with neuronal Nogo-66 receptor family members. J Biol Chem 282:5715-5725.
37. Lee H, Raiker SJ, Venkatesh K, Geary R, Robak LA, Zhang Y, Yeh HH, Shrager P, Giger RJ (2008) Synaptic function for the Nogo-66 receptor NgR1: regulation of dendritic spine morphology and activity-dependent synaptic strength. J Neurosci 28:2753-2765.
38. Lee JK, Kim JE, Sivula M, Strittmatter SM (2004) Nogo receptor antagonism promotes stroke recovery by enhancing axonal plasticity. J Neurosci 24:6209-6217.
39. Li S, Strittmatter SM (2003) Delayed systemic Nogo-66 receptor antagonist promotes recovery from spinal cord injury. J Neurosci 23:4219-4227.
40. Li S, Liu BP, Budel S, Li M, Ji B, Walus L, Li W, Jirik A, Rabacchi S, Choi E, Worley D, Sah DW, Pepinsky B, Lee D, Relton J, Strittmatter SM (2004) Blockade of nogo-66, myelin-associated glycoprotein, and oligodendrocyte myelin glycoprotein by soluble nogo-66 receptor promotes axonal sprouting and recovery after spinal injury. J Neurosci 24:10511-10520.
41. Li S, Kim JE, Budel S, Hampton TG, Strittmatter SM (2005) Transgenic inhibition of Nogo-66 receptor function allows axonal sprouting and improved locomotion after spinal injury. Mol Cell Neurosci 29:26-39.
42. Lidow MS, Koh PO, Arnsten AF (2003) D1 dopamine receptors in the mouse prefrontal cortex: immunocytochemical and cognitive neuropharmacological analyses. Synapse 47:101-108.
43. Liu BP, Fournier A, GrandPré T, Strittmatter SM (2002) Myelin-associated glycoprotein as a functional ligand for the Nogo-66 receptor. Science 297:1190-1193.
44. Liu BP, Cafferty WB, Budel SO, Strittmatter SM (2006) Extracellular regulators of axonal growth in the adult central nervous system. Philos Trans R Soc Lond B Biol Sci 361:1593-1610.
45. Liu H, Heath SC, Sobin C, Roos JL, Galke BL, Blundell ML, Lenane M, Robertson B, Wijsman EM, Rapoport JL, Gogos JA, Karayiorgou M (2002a) Genetic variation at the 22q11 PRODH2/DGCR6 locus presents an unusual pattern and increases susceptibility to schizophrenia. Proc Natl Acad Sci U S A 99:3717-3722.
46. Liu H, Abecasis GR, Heath SC, Knowles A, Demars S, Chen YJ, Roos JL, Rapoport JL, Gogos JA, KarayiorgouM (2002b) Genetic variation in the 22q11 locus and susceptibility to schizophrenia. Proc Natl Acad Sci U S A 99:16859-16864.
47. Marcus J, Dupree JL, Popko B (2002) Myelin-associated glycoprotein and myelin galactolipids stabilize developing axo-glial interactions. J Cell Biol 156:567-577.
48. McGee AW, Strittmatter SM (2003) The Nogo-66 receptor: focusing myelin inhibition of axon regeneration. Trends Neurosci 26:193-198.
49. McGee AW, Yang Y, Fischer QS, Daw NW, Strittmatter SM (2005) Experience-driven plasticity of visual cortex limited by myelin and Nogo receptor. Science 309:2222-2226.
50. Meng J, Shi Y, Zhao X, Guo S, Wang H, Zheng Y, Tang R, Feng G, Gu N, Liu H, Zhu S, He L (2007) No association between the genetic polymorphisms in the RTN4R gene and schizophrenia in the Chinese population. J Neural Transm 114:249-254.
51. Mi S, Lee X, Shao Z, Thill G, Ji B, Relton J, Levesque M, Allaire N, Perrin S, Sands B, Crowell T, Cate RL, McCoy JM, Pepinsky RB (2004) LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex. Nat Neurosci 7:221-228.
52. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408:982-985.
53. Park S, Holzman PS (1992) Schizophrenics show spatial working memory deficits. Arch Gen Psychiatry 49:975-982.
54. Park HJ, Westin CF, Kubicki M, Maier SE, Niznikiewicz M, Baer A, Frumin M, Kikinis R, Jolesz FA, McCarley RW, Shenton ME (2004) White matter hemisphere asymmetries in healthy subjects and in schizophrenia: a diffusion tensor MRI study. Neuroimage 23:213-223.
55. Park JB, Yiu G, Kaneko S, Wang J, Chang J, He XL, Garcia KC, He Z (2005) A TNF receptor family member, TROY, is a coreceptor with Nogo receptor in mediating the inhibitory activity of myelin inhibitors. Neuron 45:345-351.
56. Park JH, Widi GA, Gimbel DA, Harel NY, Lee DH, Strittmatter SM (2006) Subcutaneous Nogo receptor removes brain amyloid-β and improves spatial memory in Alzheimer's transgenic mice. J Neurosci 26:13279-13286.
57. Pritchard JK, Rosenberg NA (1999) Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet 65:220-228.
58. Pritchard JK, Stephens M, Donnelly P (2000) Inference of population structure using multilocus genotype data. Genetics 155:945-959.
59. Scambler PJ (2000) The 22q11 deletion syndromes. Hum Mol Genet 9:2421-2426.
60. Segal D, Koschnick JR, Slegers LH, Hof PR (2007) Oligodendrocyte pathophysiology: a new view of schizophrenia. Int J Neuropsychopharmacol 10:503-511.
61. Shao Z, Browning JL, Lee X, Scott ML, Shulga-Morskaya S, Allaire N, Thill G, Levesque M, Sah D, McCoy JM, Murray B, Jung V, Pepinsky RB, Mi S (2005) TAJ/TROY, an orphan TNF receptor family member, binds Nogo-66 receptor 1 and regulates axonal regeneration. Neuron 45:353-359.
62. Shenton ME, Dickey CC, Frumin M, McCarley RW (2001) A review of MRI findings in schizophrenia. Schizophr Res 49:1-52.
63. Shifman S, Bronstein M, Sternfeld M, Pisanté-Shalom A, Lev-Lehman E, Weizman A, Reznik I, Spivak B, Grisaru N, Karp L, Schiffer R, Kotler M, Strous RD, Swartz-Vanetik M, Knobler HY, Shinar E, Beckmann JS, Yakir B, Risch N, Zak NB, et al. (2002) A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet 71:1296-1302.
64. Sinibaldi L, De Luca A, Bellacchio E, Conti E, Pasini A, Paloscia C, Spalletta G, Caltagirone C, Pizzuti A, Dallapiccola B (2004) Mutations of the Nogo-66 receptor (RTN4R) gene in schizophrenia. Hum Mutat 24:534-535.
65. Slatkin M, Excoffier L (1996) Testing for linkage disequilibrium in genotypic data using the expectation-maximization algorithm. Heredity 76:377-383.
66. Spielman RS, McGinnis RE, Ewens WJ (1993) Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am J Hum Genet 52:506-516.
67. Stein MB, Schork NJ, Gelernter J (2004) A polymorphism of the beta1-adrenergic receptor is associated with low extraversion. Biol Psychiatry 56:217-224.
68. Sunyaev S, Ramensky V, Koch I, LatheW3rd, Kondrashov AS, Bork P (2001) Prediction of deleterious human alleles. Hum Mol Genet 10:591-597.
69. Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB, Starkey M, Webster MJ, Yolken RH, Bahn S (2003) Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 362:798-805.
70. Uranova N, Orlovskaya D, Vikhreva O, Zimina I, Kolomeets N, Vostrikov V, Rachmanova V (2001) Electron microscopy of oligodendroglia in severe mental illness. Brain Res Bull 55:597-610.
71. Uranova NA, Vostrikov VM, Orlovskaya DD, Rachmanova VI (2004) Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr Res 67:269-275.
72. Usiskin SI, Nicolson R, Krasnewich DM, Yan W, Lenane M, Wudarsky M, Hamburger SD, Rapoport JL (1999) Velocardiofacial syndrome in childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry 38:1536-1543.
73. Wang KC, Kim JA, Sivasankaran R, Segal R, He Z (2002) P75 interacts with the Nogo receptor as a co-receptor for Nogo, MAG and OMgp. Nature 420:74-78.
74. Wang X, Chun SJ, Treloar H, Vartanian T, Greer CA, Strittmatter SM (2002) Localization of Nogo-A and Nogo-66 receptor proteins at sites of axon-myelin and synaptic contact. J Neurosci 22:5505-5515.
75. Wang X, Baughman KW, Basso DM, Strittmatter SM (2006) Delayed Nogo receptor therapy improves recovery from spinal cord contusion. Ann Neurol 60:540-549.
76. Wong ST, Henley JR, Kanning KC, Huang KH, Bothwell M, Poo MM (2002) A p75(NTR) and Nogo receptor complex mediates repulsive signaling by myelin-associated glycoprotein. Nat Neurosci 5:1302-1308.
77. Yang BZ, Zhao H, Kranzler HR, Gelernter J (2005) Practical population group assignment with selected informative markers: characteristics and properties of Bayesian clustering via STRUCTURE. Genet Epidemiol 28:302-312.